These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15888191)

  • 21. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series.
    Yamauchi PS; Mau N
    J Am Acad Dermatol; 2009 Jul; 61(1):158-60. PubMed ID: 19539861
    [No Abstract]   [Full Text] [Related]  

  • 22. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The return of investment of translational research in inflammatory dermatoses.
    van de Kerkhof PC
    J Dermatolog Treat; 2008; 19(6):317. PubMed ID: 18982511
    [No Abstract]   [Full Text] [Related]  

  • 24. Eosinophilia during psoriasis treatment with TNF antagonists.
    Malisiewicz B; Murer C; Pachlopnik Schmid J; French LE; Schmid-Grendelmeier P; Navarini AA
    Dermatology; 2011; 223(4):311-5. PubMed ID: 22301393
    [No Abstract]   [Full Text] [Related]  

  • 25. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
    Takahashi MD; Castro LG; Romiti R
    Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H
    Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
    Brunasso AM; Puntoni M; Delfino C; Massone C
    Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
    [No Abstract]   [Full Text] [Related]  

  • 28. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consecutive use of different biological therapies in the treatment of psoriasis.
    Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
    Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
    [No Abstract]   [Full Text] [Related]  

  • 30. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab.
    Hertl MS; Haendle I; Schuler G; Hertl M
    Br J Dermatol; 2005 Mar; 152(3):552-5. PubMed ID: 15787827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Misunderstandings.
    Feldman SR
    J Dermatolog Treat; 2007; 18(1):4. PubMed ID: 17365258
    [No Abstract]   [Full Text] [Related]  

  • 32. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
    Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
    Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
    Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
    Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of severe psoriasis with anti-TNF-alpha-antibody and methotrexate].
    Dalaker M; Bonesrønning JH
    Tidsskr Nor Laegeforen; 2003 Apr; 123(8):1070-1. PubMed ID: 12760225
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of psoriasis with adalimumab.
    Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM
    Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab for the treatment of extensive plaque psoriasis--regulation, cost and reimbursement.
    Rabinovich M; Fainaru M
    Isr Med Assoc J; 2003 Nov; 5(11):817-8. PubMed ID: 14650110
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.
    Ardigò M; Giuliani A; de Felice C; Mastroianni A; Berardesca E
    J Drugs Dermatol; 2008 Oct; 7(10):935-9. PubMed ID: 19112756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
    Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
    Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S; Mizuno K; Adachi M
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alemtuzumab and chronic plaque psoriasis.
    Aslam A; Marsland AM; Rog D; Griffiths CE
    Br J Dermatol; 2013 Jul; 169(1):184-6. PubMed ID: 23834118
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.